Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of ALS diagnosis of less than 5 years.~* Greater than 6 fasciculations per minute noted at least in the tongue by clinical, ultrasound, or EMG evaluation.~* Normal oral cavity exam at screening.~Exclusion Criteria:~* Presence of clinically significant or unstable condition that would result in an increased risk of study participation or difficulty in interpretation of the study results.~* Tremor or other movement disorder that would interfere with recording.~* Presence of major gastrointestinal disorders, such as inflammatory bowel disease, diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or esophageal lesions/ulcers.~* Presence of laryngospasm or significant swallowing problems.~* Inability to tolerate a spicy sensation in the mouth or stomach.~* Actively using illicit drugs or history of chronic substance abuse within the past year prior to screening, including abuse of alcohol.~* Participated in a clinical study (except natural history studies without administration of an investigational product) within 30 days prior to screening.~* Pregnant, breastfeeding, or planning to become pregnant.~* Blood pressure of ≥160 mmHg systolic and/or ≥100 mmHg diastolic.~* Clinically significant abnormalities in laboratory findings (including screening complete electrolyte panel, complete blood count, liver function tests).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLX-787-ODT (orally disintegrating tablet) (Type: EXPERIMENTAL): Single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).